Key result
Rotavirus vaccines have dramatically reduced the incidence of severe rotavirus diarrhea, with decreases of over 80% in high-income countries and about 50% in low-income settings.
Rotavirus vaccines have successfully reduced global diarrheal disease burden, but universal implementation and improving efficacy in low-income countries remain critical challenges.
Supports rotavirus vaccination programs; leaves open strategies to close efficacy gaps in low-income settings.
Approximately 40 years have passed since the discovery of the rotavirus and 10 years since the introduction and progressive dissemination of rotavirus vaccines worldwide. Currently, 92 countries have introduced rotavirus vaccines into national or subnational programs with evident impact in disease reduction. Two vaccines have been widely used, and four additional vaccines have been licensed and are being used in defined regions. In this context, one main issue that remains unsolved is the lower vaccine efficacy/effectiveness in low-income countries. An additional partially answered issue relates to rotavirus strain circulation in vaccinated populations. These issues are discussed in this review. The most imperative challenge ahead is to fulfill the WHO's recommendation to introduce rotavirus vaccines in all countries.
No takes yet. Share an insight, caveat, or question.
Miguel O’Ryan (2017) conducted a review in Rotavirus gastroenteritis. Rotavirus vaccines was evaluated. Rotavirus vaccines have dramatically reduced the incidence of severe rotavirus diarrhea, with decreases of over 80% in high-income countries and about 50% in low-income settings.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: